Madrigal's massive siRNA licensing deal signals a dangerous consolidation in the MASH drug race. The real winner isn't the patient.
The new Medicare drug price negotiation list isn't about saving seniors money; it’s a calculated political strike against Big Pharma.
The hype around BBB-crossing antibody technology masks a brutal reality. Is this truly a breakthrough, or just another pharmaceutical mirage in the fight against neurodegeneration?
A new fluorescent technology promises drug response tracking, but the real story is about Big Pharma's control over clinical trial visibility.
Aurobindo's CuraTeQ just snagged Health Canada approval for Dyrupeg, but this isn't just a regulatory win; it's a calculated strike in the escalating global **biosimilar market** battle.
The latest healthcare fiasco isn't about access; it's about who profits from the chaos. Analyzing the true victims of US healthcare.